Figure 3.

YKT6 expression is elevated in HNSCC/OSCC samples from publicly available datasets.(a-b) Correlations between YKT6 level and clinicopathological characteristics (including HNSCC subtypes). (c-e) Boxplot indicating YKT6 expression in different grades, HPV infection condition, TP53 mutation status of HNSCC samples from the UALCAN database. (f-i) Analysis of YKT6 mRNA expression in different subtypes of HNSCC tissues from TCGA database. (j) Analysis of mRNA expression of YKT6 in OSCC and normal control tissues from GSE30784 dataset. (k) Quantification of YKT6 mRNA in metastatic lymph nodes and normal oral tissues from GSE78060. (l-m) The correlation between YKT6 mRNA expression with immune score and tumour purity in the GSE30784 and GSE41613 datasets. (n) Deletion, diploid, copy number gain and amplification are involved in the deregulation of YKT6 expression as analyzed by cBioPortal using TCGA-HNSCC data. (o) Correlation between YKT6 CNV and mRNA expression. (p) The location of CNV of YKT6 on 23 chromosomes using TCGA-HNSCC cohort. (q) DNA methylation value differences in normal control and tumour tissues from UALCAN-HNSCC cohort. (r) The correlation of YKT6 expression and DNA methylation level in MEXPRESS-HNSCC cohort; *p < 0.05, **p ≤ 0.01, and ***p ≤ 0.001